Axillary lymphadenopathy after a COVID-19 vaccine booster dose has a mean time to resolution of 102 days, shorter than the time to resolution after the initial series.

64-year-old woman who underwent screening mammography and breast ultrasound. A, right, and B, left, mediolateral oblique views obtained 2 days after booster dose of Pfizer COVID-19 vaccine administered in left upper extremity shows left axillary lymphadenopathy. No right axillary lymphadenopathy was visualized. C, left axillary ultrasound performed same day as mammogram shows enlarged left axillary lymph node (calipers) with thickened cortex, measuring 6 mm. D, left axillary ultrasound performed 102 days after booster dose shows normal lymph node (calipers) with cortical thickness of 2 mm, consistent with resolution of lymphadenopathy.


March 13, 2023 — According to an accepted manuscript published in ARRS’ American Journal of Roentgenology (AJR), axillary lymphadenopathy after a COVID-19 vaccine booster dose has a mean time to resolution of 102 days, shorter than the time to resolution after the initial series. 

 “Findings support a follow-up interval of at least 12 weeks, as well as avoidance of delaying screening mammography, for suspected vaccine-related lymphadenopathy after booster doses,” concluded first author Eralda Mema, MD, of Weill Cornell Imaging at New York Presbyterian

This AJR accepted manuscript retrospectively studied 54 patients (mean age, 57 years) at a single institution with unilateral axillary lymphadenopathy ipsilateral to a booster dose of mRNA COVID-19 vaccine visualized on ultrasound—whether an initial breast imaging examination or follow-up to prior screening or diagnostic breast imaging—performed between September 1, 2021 and December 31, 2022, and who underwent follow-up ultrasound examinations until resolution of lymphadenopathy. Electronic medical records were used to extract patient information. 

Ultimately, axillary lymphadenopathy related to a booster dose of a COVID-19 vaccine resolved at a mean of 102 days after the booster dose and 84 days after the initial ultrasound examination showing the lymphadenopathy. Neither age, vaccine booster brand (Moderna vs. Pfizer), nor breast cancer history were significantly associated with time to resolution in univariable or multivariable analyses (all p>.05). 

Noting exclusions due to incomplete or even unavailable vaccination history, patients were also excluded if follow-up imaging was pending, “which may have biased the sample toward inclusion of patients whose lymphadenopathy resolved rapidly,” the authors of this AJR accepted manuscript acknowledged

For more information: www.arrs.org 


Related Content

News | Breast Imaging

March 15, 2023 — In a study of over a million women, digital breast tomosynthesis (DBT) showed improved breast cancer ...

Time March 15, 2023
arrow
News | Lung Imaging

March 15, 2023 — According to an accepted manuscript published in ARRS’ own American Journal of Roentgenology (AJR) ...

Time March 15, 2023
arrow
News | Mammography

March 14, 2023 — Volpara Health Technologies, a global leader in software for the early detection of breast cancer ...

Time March 14, 2023
arrow
News | Artificial Intelligence

March 10, 2023 — Breast cancer undisputedly has the highest incidence rate in female patients. Moreover, out of the six ...

Time March 10, 2023
arrow
Feature | Breast Density

March 9, 2023 — Today, the U.S. Food and Drug Administration published updates to the mammography regulations to, among ...

Time March 09, 2023
arrow
News | Breast Density

March 9, 2023 — Research focused on the use of AI in breast screening was presented by Volpara Health Technologies Ltd ...

Time March 09, 2023
arrow
Feature | Women's Health | By Paola Wisner, Andy Smith, PhD, and Nikos Gkanatsios, PhD

Mammography has long been a vital tool in the radiologist toolkit for breast cancer imaging. It is an essential ...

Time March 09, 2023
arrow
News | Artificial Intelligence

March 2, 2023 — Qure.ai, a London-based medical Artificial Intelligence (AI) imaging company, has announced a new ...

Time March 02, 2023
arrow
News | Computed Tomography (CT)

March 1, 2023 — According to an accepted manuscript published in ARRS’ American Journal of Roentgenology (AJR), using a ...

Time March 01, 2023
arrow
Sponsored Content | Whitepapers | Mammography

Fujifilm’s third generation digital mammography system, ASPIRE Cristalle (known as AMULET Innovality outside the United ...

Time February 28, 2023
arrow
Subscribe Now